S Hirohara

Summary

Country: USA

Publications

  1. ncbi request reprint Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer
    Tadashi Uwagawa
    Department of Surgery, The Jikei University School of Medicine, 3 19 18 Nishi shinbashi, Minato ku, Tokyo, 106 8471, Japan
    Cancer Chemother Pharmacol 75:191-6. 2015
  2. ncbi request reprint Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
    Tadashi Uwagawa
    Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
    Am J Clin Oncol 36:44-8. 2013
  3. ncbi request reprint A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
    T Uwagawa
    Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
    Ann Oncol 20:239-43. 2009
  4. ncbi request reprint Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation
    Tadashi Uwagawa
    Department of Surgery, Jikei University School of Medicine, 3 25 8 Nishi shinbashi, Minato ku, Tokyo 105 8461, Japan
    Anticancer Res 29:3173-8. 2009
  5. ncbi request reprint Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients
    Tadashi Uwagawa
    Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
    J Palliat Med 13:815-8. 2010

Collaborators

  • Takeyuki Misawa
  • Yasuro Futagawa
  • Hiroaki Shiba
  • Tadashi Uwagawa
  • Katsuhiko Yanaga
  • Takeshi Gocho
  • Taro Sakamoto
  • T Uwagawa
  • Daigo Hata
  • Keisuke Aiba
  • Norimitsu Okui
  • Kyohei Abe
  • Shunichi Sadaoka
  • Ryusuke Ito
  • Nobuhiro Tsutsui
  • Shigeki Wakiyama
  • Tomonori Iida
  • T Sakamoto
  • K Yanaga
  • S Sadaoka
  • R Ito
  • Paul J Chiao
  • S Wakiyama
  • T Gocho

Detail Information

Publications5

  1. ncbi request reprint Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer
    Tadashi Uwagawa
    Department of Surgery, The Jikei University School of Medicine, 3 19 18 Nishi shinbashi, Minato ku, Tokyo, 106 8471, Japan
    Cancer Chemother Pharmacol 75:191-6. 2015
    ..The aim of this study was to determine the dose-limiting toxicity (DLT), maximum-tolerated dose, and a recommended phase II dose of S-1. Response was assessed as a secondary endpoint...
  2. ncbi request reprint Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
    Tadashi Uwagawa
    Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
    Am J Clin Oncol 36:44-8. 2013
    ....
  3. ncbi request reprint A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
    T Uwagawa
    Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan
    Ann Oncol 20:239-43. 2009
    ..The secondary end point was to assess therapeutic response...
  4. ncbi request reprint Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation
    Tadashi Uwagawa
    Department of Surgery, Jikei University School of Medicine, 3 25 8 Nishi shinbashi, Minato ku, Tokyo 105 8461, Japan
    Anticancer Res 29:3173-8. 2009
    ..In this study, whether or not nafamostat mesilate could enhance the anticancer effect of gemcitabine was investigated...
  5. ncbi request reprint Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients
    Tadashi Uwagawa
    Department of Surgery, Jikei University School of Medicine, Tokyo, Japan
    J Palliat Med 13:815-8. 2010
    ..GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms...